Target INR for Atrial Fibrillation on Warfarin
For patients with nonvalvular atrial fibrillation on warfarin (Coumadin), the target INR is 2.5 with a therapeutic range of 2.0 to 3.0.
This recommendation is consistent across multiple high-quality guidelines and the FDA drug label 1, 2, 3.
Evidence-Based Rationale
The 2019 AHA/ACC/HRS Focused Update provides Class I, Level of Evidence A recommendations that warfarin should be dosed to achieve an INR of 2.0 to 3.0 for patients with nonvalvular AF who have a CHA₂DS₂-VASc score of 2 or greater in men or 3 or greater in women 2. The 2014 AHA/ACC/HRS guideline similarly recommends this same INR range with Level of Evidence A 1.
The FDA-approved Coumadin label explicitly states that for patients with nonvalvular AF, warfarin should target an INR of 2.5 (range 2.0-3.0) 3. This applies regardless of whether the AF is paroxysmal, persistent, or permanent 1.
The most recent 2024 ESC guidelines reaffirm that a target INR of 2.0-3.0 is recommended for patients with AF prescribed a VKA for stroke prevention (Class I, Level of Evidence B) 4.
Special Populations
Mechanical Heart Valves
- Aortic position (bileaflet or Medtronic Hall valves): Target INR 2.5 (range 2.0-3.0) 1, 3
- Mitral position (tilting disk or bileaflet valves): Target INR 3.0 (range 2.5-3.5) 1, 3
- Caged ball or caged disk valves: Target INR 3.0 (range 2.5-3.5) 3
End-Stage Renal Disease
For patients with AF and end-stage CKD (CrCl <15 mL/min) or on hemodialysis with CHA₂DS₂-VASc score ≥2, warfarin with INR 2.0-3.0 is reasonable (Class IIa recommendation), as DOACs are not recommended in this population 1.
Critical Monitoring Requirements
INR monitoring frequency 1, 2:
- During initiation: Check INR at least weekly
- When stable: Check INR at least monthly
The 2018 CHEST guideline emphasizes that time in therapeutic range (TTR) should be at least 65% to maximize efficacy and safety 5. Poor INR control (TTR <65%) should prompt consideration of switching to a DOAC 2.
Evidence Against Lower INR Targets
While some Asian studies have explored lower INR targets (1.5-2.0 or 1.6-2.6), a 2020 systematic review and meta-analysis of 79 RCTs (n=12,928) found that lower INR targets significantly increased thromboembolism risk (RR 1.50,95% CI 1.29-1.74) compared to standard targets 6. Although lower targets reduced major bleeding (RR 0.54), mortality was unchanged. The authors concluded that an INR range of 2.0-3.0 should remain standard 6.
A 2018 pooled analysis of modern warfarin trials found that INR between 2.0 and 2.5 provides the best balance between ischemic stroke and intracranial hemorrhage, with risk increasing when INR falls below 2.0 or exceeds 3.0 7.
Common Pitfalls to Avoid
Do not use lower INR targets (e.g., 1.5-2.0) based on age alone, even in elderly patients ≥75 years. While older guidelines suggested this might be considered (Class IIb) 8, current evidence does not support routine use of lower targets 6.
Do not withhold anticoagulation based on AF pattern. The temporal pattern (paroxysmal vs. persistent vs. permanent) should not determine the need for anticoagulation 1, 2.
INR >4.0 provides no additional benefit and significantly increases bleeding risk 3. INR >3.5 is associated with exponentially increased intracranial hemorrhage risk 5.
Single "one-off" INR values are insufficient. Focus on TTR as the quality measure, aiming for individual TTR >65% 5.